PD L1 News and Research

RSS

Researchers find new marker for better prognosis in gastric and esophageal cancer

Tumors that develop at the transition of the stomach to the esophagus, so-called adenocarcinomas of the gastroesophageal transition, are still difficult to treat and the chances of recovery are still low.

2 Jul 2018

Research shows why new cancer therapies fail to work on some patients

University of Otago research provides insights into an underlying mechanism that could explain why new cancer therapies to help treat metastatic melanoma do not always work on patients, paving the way for predicting which patients will benefit from certain drugs.

30 Jun 2018

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

4 May 2018

New study evaluates expression of PD-L1 in human medulloblastoma

This study evaluated the expression of PD-L1 and markers of immune mediated resistance in human medulloblastoma, the most common malignant pediatric brain tumor.

3 May 2018

New vaccine strategy increases number of tumor-specific cancer-killing T cells

New research published in Cancer Immunology Research by Drs. Esteban Celis and Hussein Sultan of the Georgia Cancer Center at Augusta University could serve as the stepping-stone in constructing vaccines with a greater likelihood of finding and attacking tumors in the human body.

2 May 2018

Researchers discover new information related to rare form of leukemia

International research consortium led by researchers from the University of Helsinki, Finland, discovered new information related to a rare form of leukemia called aggressive NK-cell leukemia.

20 Apr 2018

Precancerous colon polyps in Lynch syndrome patients display immune activation

Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation well before cancer development, according to research from The University of Texas MD Anderson Cancer Center.

16 Apr 2018

Study provides systematic view of gene enhancer activity in diverse tumors

At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.

5 Apr 2018

Researchers unravel immunopathogenesis of Johne's disease

A research team has unraveled the immunopathogenesis of Johne's disease, a chronic bovine disease that has caused endemics in Japan and many other countries, placing financial burdens on cattle farmers.

2 Apr 2018

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

Johns Hopkins researchers invent new class of immunotherapy drugs to fight cancer

Johns Hopkins researchers have invented a new class of cancer immunotherapy drugs that are more effective at harnessing the power of the immune system to fight cancer.

2 Mar 2018

Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism

Novel bifunctional immunotherapeutic agents have been developed that, as well as deactivating key immune checkpoints,deactivate the tumor's protective response.

23 Feb 2018

FDA approves first treatment to reduce risk of NSCLC progression

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

18 Feb 2018

Study reports longer survival for obese men with metastatic melanoma

Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index, investigators report in a study published in Lancet Oncology of 1,918 patients in six independent clinical cohorts.

13 Feb 2018

Study lays groundwork for using PD-1 inhibitors against aggressive form of pediatric brain cancer

One type of immunotherapy removes a genetic blindfold that cancer uses to hide from the immune system. These "PD-1 inhibitors", including drugs like pembrolizumab, nivolumab and atezolizumab, have proven useful and have even in some cases revolutionized the treatment of common adult cancers ranging from melanoma, to lung cancer, to kidney cancer and more.

30 Jan 2018

Leading medical societies update molecular testing guideline for lung cancer

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

24 Jan 2018

Patients with desmoplastic melanoma respond well to immunotherapy

Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients.

11 Jan 2018

Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

OBD presents results of immunotherapy studies at FNIH Biomarker Consortium Cancer Steering Committee’s annual meeting

Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, presented its latest results at the annual meeting of the Foundation for National Institute for Health Biomarker Consortium Cancer Steering Committee, held in Washington, DC on 6-7 November 2017.

22 Nov 2017